Last edition
News about "Age-related Macular Degeneration (AMD)"
ExSight Ventures Invests in RevOpsis Therapeutics to Develop Eye Disease Therapies
RevOpsis is developing a novel class of multi-specific antibody-based treatments designed to address significant unmet needs in ophthalmology, with an initial focus on wet Age-related Macular Degeneration (AMD) and diabetic eye disease.
Age-related Macular Degeneration (AMD) | 17/09/2025 | By Dineshwori
Sanofi Drug Earns Fast Track Status for Wet AMD in US
Sanofi is evaluating SAR402663 in a Phase 1/2 trial (NCT06660667) for neovascular AMD. The gene therapy targets abnormal blood vessel growth, reduces retinal damage, and aims to eliminate the need for frequent intravitreal injections.
Age-related Macular Degeneration (AMD) | 11/09/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy